High Risk Neuroblastoma Study 2: A randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma.
Patients with high-risk neuroblastoma (HR-NBL) are currently offered multimodal treatment including induction chemotherapy, high-dose chemotherapy (HDC) followed by autologous stem cell rescue (ASCR), local treatment (surgery and radiotherapy) and maintenance treatment. Despite all these treatments, the outcome often remains poor.
In HR-NBL2, we look to define the most effective threatment at each stage by comparing 2 therapies offered at 3 separate randomisation steps: at induction (RAPID COJEC (SIOPEN) vs N5-N6 regimens), at HDC (single HDC vs tandem HDC+Thiotepa), and at local radiotherapy (standard dose vs an increased radiotherapy dose).
Dr Dominique Valteau Couanet
Gustave Roussy (Villejuif, France)
UK Lead Investigator
Dr Martin Elliott
Leeds Children’s Hospital